Skip to main content
SpringerLink
Log in

High-risk clinical stage I NSGCT: the case for RPLND

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Introduction

High-risk clinical stage I NSGCT patients are at significant risk of harbouring occult metastatic disease. In these patients, treatment options consist of retroperitoneal lymph node dissection (RPLND) or two cycles of primary BEP chemotherapy. Both these options provide a nearly 100% cure rate.

Materials and methods

We review the rationale for both treatments.

Conclusions

Advantages of RPLND include high cure rate with single modality therapy eliminating the need for chemotherapy with its attendant long-term toxicities in the majority of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stephenson AJ, Bosl GJ, Motzer RJ et al (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. Impact of patient selection factors on outcome. J Clin Oncol 23(12):2781–2788. doi:10.1200/JCO.2005.07.132

    Google Scholar 

  2. Vergouwe Y, Steyerberg EW, Eijkemans MJ et al (2003) Predictors of occult metastasis in clinical stage I non-seminoma: a systematic review. J Clin Oncol 21(22):4092–4099. doi:10.1200/JCO.2003.01.094

    Article  PubMed  Google Scholar 

  3. Read G, Stenning SP, Cullen MH et al (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10(11):1762–1768

    PubMed  CAS  Google Scholar 

  4. Heidenreich A, Sesterhenn IA, Mostofi FK et al (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk of metastasis. Cancer 83(5):1002–1011. doi:10.1002/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.0.CO;2-A

    Article  PubMed  CAS  Google Scholar 

  5. Nicolai N, Miceli R, Artusi R et al (2004) A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 171(1):172–176. doi:10.1097/01.ju.0000101513.64777.f2

    Article  PubMed  Google Scholar 

  6. Sogani PC, Perrotti M, Herr HW et al (1998) Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 159(3):855–858. doi:10.1016/S0022-5347(01)63753-4

    Article  PubMed  CAS  Google Scholar 

  7. Hermans BP, Sweeney CJ, Foster RS et al (2000) Risk of systematic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 163(6):1721–1724. doi:10.1016/S0022-5347(05)67528-3

    Article  PubMed  CAS  Google Scholar 

  8. Stephenson AJ, Bosl GJ, Bajorin DF et al (2005) Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 174:557–560. doi:10.1097/01.ju.0000165163.03805.37

    Article  PubMed  Google Scholar 

  9. Albers P, Siener R, Krege S et al (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26(18):2966–2972. doi:10.1200/JCO.2007.12.0899

    Article  PubMed  CAS  Google Scholar 

  10. Donohue JP, Thornhill JA, Foster RS et al (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149:237–243

    PubMed  CAS  Google Scholar 

  11. Biological Effects of Ionizing Radiation (BEIR) VII Report (2006) Health risks from exposure to low levels of ionizing radiation

  12. Tarin TV, Sonn G, Shinghal R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage 1 testicular cancer using computerized tomography. J Urol 181:627–633. doi:10.1016/j.juro.2008.10.005

    Article  PubMed  Google Scholar 

  13. Foster RS, Baniel J, Leibovitch I et al (1996) Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol 155:1943. doi:10.1016/S0022-5347(01)66053-1

    Article  PubMed  CAS  Google Scholar 

  14. Ehrlich Y, Baniel J (2007) Late relapse of testis cancer. Urol Clin North Am 34(2):253–258. doi:10.1016/j.ucl.2007.02.012

    Article  PubMed  Google Scholar 

  15. Choueiri TK, Stephenson AJ, Gilligan T et al (2007) Management of clinical stage I nonseminomatous germ cell testicular cancer. Urol Clin North Am 34:137–148. doi:10.1016/j.ucl.2007.02.001

    Google Scholar 

  16. Gospodarowicz M (2008) Testicular cancer patients: considerations in long- term follow-up. Hematol Oncol Clin North Am 22:245–255. doi:10.1016/j.hoc.2008.01.003

    Article  PubMed  Google Scholar 

  17. Fossa SD, Aass N, Harvei S et al (2004) Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 90:607–612. doi:10.1038/sj.bjc.6601558

    Article  PubMed  CAS  Google Scholar 

  18. Pentheroudakis G, Pavlidis N (2007) Late toxicity in survivors from adolescent cancers. Cancer Treat Rev 33(7):656–663. doi:10.1016/j.ctrv.2007.06.002

    Article  PubMed  Google Scholar 

  19. Travis LB, Fossa S, Schonfeld S et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97(18):1354–1365

    Article  PubMed  Google Scholar 

  20. van Leeuwen FE (1999) Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clin Haematol 9(1):57–85. doi:10.1016/S0950-3536(96)80037-0

    Google Scholar 

  21. Kollmannsberger C, Kuzcyk M, Mayer F et al (1999) Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 17:275–281. doi:10.1002/(SICI)1098-2388(199912)17:4<275::AID-SSU9>3.0.CO;2-U

    Article  PubMed  CAS  Google Scholar 

  22. Abouassaly R, Klein EA, Raghavan D (2005) Complications of surgery and chemotherapy for testicular cancer. Urol Oncol 23(6):447–455. doi:10.1016/j.urolonc.2005.06.006

    PubMed  Google Scholar 

  23. Efstathiou E, Logothetis CJ (2006) Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Cancer Netw 4(10):1059–1070

    CAS  Google Scholar 

  24. Lackner JE, Mark I, Schatzl G et al (2007) Hypogonadism and androgen deficiency symptoms I testicular cancer survivors. Urology 69(4):754–758. doi:10.1016/j.urology.2007.01.002

    Article  PubMed  Google Scholar 

  25. Hartmann JT, Kollmannsberger C, Kanz L et al (1999) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83(6):866. doi:10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9

    Article  PubMed  CAS  Google Scholar 

  26. Strumberg D, Brugge S, Korn MW et al (2002) Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13(2):229–236. doi:10.1093/annonc/mdf058

    Article  PubMed  CAS  Google Scholar 

  27. Oh JH, Baum DD, Pham S et al (2007) Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol 24(2):175–181. doi:10.1007/BF02698037

    Article  PubMed  CAS  Google Scholar 

  28. Bokemeyer C, Berger CC, Hartmann JT et al (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77(8):1355–1362

    PubMed  CAS  Google Scholar 

  29. van den Belt-Dusebout AW, de Wit R, Gietema JA et al (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25(28):4370–4378. doi:10.1200/JCO.2006.10.5296

    Article  PubMed  Google Scholar 

  30. Kaufman MR, Chang SS (2007) Short- and long-term complications. Urol Clin North Am 34(2):259–268. doi:10.1016/j.ucl.2007.02.011

    Article  PubMed  Google Scholar 

  31. Licciardello JT, Moake JL, Rudy CK et al (1985) Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42:296–300

    Article  PubMed  CAS  Google Scholar 

  32. Carver BS, Shayegan B, Eggener S et al (2007) Incidence of metastatic non-seminomatous germ cell tumor outside the boundaries of a modified post-chemotherapy retroperitoneal lymph node dissection. JCO 25(28):4365–4369. doi:10.1200/JCO.2007.11.2078

    Article  Google Scholar 

Download references

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, B3 Urology, The Ottawa Hospital, 1053 Carling Avenue, Ottawa, ON, K1Y 4E9, Canada

    Christopher Morash & Ilias Cagiannos

Authors
  1. Christopher Morash
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilias Cagiannos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ilias Cagiannos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morash, C., Cagiannos, I. High-risk clinical stage I NSGCT: the case for RPLND. World J Urol 27, 449–453 (2009). https://doi.org/10.1007/s00345-009-0425-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-009-0425-x

Keywords

Search

Navigation